Join the 'Chronic Obstructive Pulmonary Disease, Maintenance' group to help and get support from people like you.

Chronic Obstructive Pulmonary Disease, Maintenance Blog

Related terms: COPD, Maintenance

Once-Daily Striverdi Respimat Inhaler Approved for COPD

Posted 11 hours ago by Drugs.com

THURSDAY, July 31, 2014 – Striverdi Respimat (olodaterol) inhalation spray has been approved by the U.S. Food and Drug Administration to treat chronic obstructive pulmonary disease (COPD), the agency said Thursday in a news release. COPD, which includes chronic bronchitis and chronic emphysema, is a progressive disease that makes breathing difficult by obstructing airflow through the lungs. Most commonly caused by smoking, it's the third-leading cause of death in the United States, the FDA said. The once-daily inhaler relaxes lung airways, improving breathing. It was evaluated in a clinical study of more than 3,100 people diagnosed with COPD. The drug's label will carry a boxed warning that it increases the risk of asthma-related death. The FDA said Striverdi Respimat hasn't been evaluated among people with asthma and is not approved to treat asthma or sudden breathing problems such as ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease

Posted 12 hours ago by Drugs.com

July 31, 2014 – Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema that are experiencing airflow obstruction. Striverdi Respimat can be used once daily over a long period of time. COPD is a serious lung disease that makes breathing difficult and worsens over time. Symptoms can include wheezing, cough, chest tightness, and shortness of breath. Cigarette smoking is the leading cause of COPD. According to the National Heart, Lung, and Blood Institute, COPD is the third leading cause of death in the United States. “The availability of this new long-term maintenance medication provides an additional treatment options for the millions of Americans who suffer with COPD,” said Curtis Rosebraugh, M.D., M.P.H., director of the Off ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

Annual COPD Costs To Hit $49 Billion by 2020: CDC

Posted 1 day 13 hours ago by Drugs.com

WEDNESDAY, July 30, 2014 – Medical costs for chronic obstructive pulmonary disease (COPD) in the United States are more than $32 billion each year, according to new research from the U.S. Centers for Disease Control and Prevention. The yearly financial toll of COPD (which includes emphysema and chronic bronchitis) is expected to reach an estimated $49 billion by 2020. "For the first time, our analyses provide state-specific costs for COPD, which provide state public health practitioners with estimates of the economic burden of COPD within their borders and illustrates the potential medical and absenteeism costs savings to states through implementing state level programs that are designed to prevent the onset of COPD," Dr. Earl Ford, of the CDC's division of population health, said in a news release from the journal CHEST. Medical costs associated with COPD were primarily paid for by ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD

Posted 6 May 2014 by Drugs.com

London UK - 30 April 2014, GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium is GSK’s first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonist (LAMA), and is contained in the Ellipta® inhaler. The FDA-approved strength is 62.5 mcg. Following this approval by the FDA, it is anticipated that launch activities in the US will commence during the fourth quarter of 2014. The phase III pivotal programme for umeclidinium included seven clinical studies which involved over 2,500 COPD patients treated with umeclidinium or placebo. About CO ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance

FDA Approves Anoro Ellipta to Treat Chronic Obstructive Pulmonary Disease

Posted 18 Dec 2013 by Drugs.com

December 18, 2013 – The U.S. Food and Drug Administration today approved Anoro Ellipta (umeclidinium and vilanterol inhalation powder) for the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). COPD is a serious lung disease that makes breathing difficult and worsens over time. Symptoms can include chest tightness, chronic cough and excessive phlegm. Cigarette smoking is the leading cause of COPD. According to the National Heart, Lung, and Blood Institute, COPD is the third leading cause of death in the United States. “Anoro Ellipta works by helping the muscles around the airways of the lungs stay relaxed to increase airflow in patients with COPD,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “The availability of new ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute, COPD, Chronic Obstructive Lung Disease, COPD, Maintenance, Chronic Obstructive Airway Disease, COPD, Acute

Certain COPD Meds Might Raise Heart Risks, Study Says

Posted 20 May 2013 by Drugs.com

MONDAY, May 20 – Long-acting inhaled medications used by millions of people with chronic obstructive pulmonary disease (COPD) may raise the risk of cardiovascular complications among older patients, a new large Canadian study reveals. The finding centers around patients over age 65 who are prescribed long-acting bronchodilators – either anticholinergics (such as Spiriva) or beta-agonists (such as Serevent). Both medications are commonly used to relieve the shortness of breath that characterizes moderate to severe COPD and to improve lung function. The team found that compared with patients who do not use either medication, those using either of these bronchodilators face a notably higher risk for experiencing a cardiac event, such as heart attack or heart failure. "The bad news is that, although everybody's different, there's a chance that by using these long-acting bronchodilators ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Albuterol, Spiriva, Chronic Obstructive Pulmonary Disease, Maintenance, Ventolin, Epinephrine, Xopenex, ProAir HFA, Ipratropium, Proventil, Atrovent, Chronic Obstructive Pulmonary Disease, Acute, Primatene Mist, Salmeterol, EpiPen, Ventolin HFA, Spiriva HandiHaler, Tiotropium, Alupent, Formoterol

Health Tip: Help Keep COPD in Check

Posted 31 Aug 2012 by Drugs.com

-- Chronic obstructive pulmonary disorder (COPD) is an umbrella term for lung diseases that make it difficult to breathe. Primary examples include chronic bronchitis and emphysema. The U.S. National Heart Lung and Blood Institute offers these suggestions to help keep COPD under control: Avoid exposure to lung irritants whenever possible. Have regular medical checkups. Perform daily activities slowly. Devise easier ways to perform daily chores, such as cooking and cleaning. Ask loved ones for help rearranging your home to avoid frequent use of stairs. Wear loose clothing that's easy to put on and take off. Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Screening for Other Health Problems May Aid COPD Survival

Posted 4 May 2012 by Drugs.com

FRIDAY, May 4 – People with the often deadly lung condition chronic obstructive pulmonary disease, or COPD, have an increased risk of death if they also have certain types of other health problems, according to new research. COPD is a progressive disease involving bronchitis and emphysema, often tied to smoking, that makes it hard for patients to breathe. The new study included more than 1,600 COPD patients in the United States and Spain who were followed-up for an average of 51 months. The findings were released online May 4 ahead of print publication in the American Journal of Respiratory and Critical Care Medicine. The researchers looked at 79 other health problems in the COPD patients and found that "12 were significantly and independently associated with an increased risk of death," lead study author Dr. Miguel Divo, a physician in the pulmonary and critical division at Brigham ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Many Ignore Symptoms of Lung Disease, Study Finds

Posted 1 Dec 2011 by Drugs.com

THURSDAY, Dec. 1 – Americans' awareness of chronic obstructive pulmonary disease (COPD) is rising, but many of those at risk don't talk to their doctor about symptoms, according to a new survey by the U.S. National Heart, Lung, and Blood Institute. Symptoms of COPD – the third-leading cause of death in the United States – include shortness of breath, chronic coughing or wheezing, excess sputum production and a feeling of not being able to take a deep breath. COPD affects 24 million people in the United States, but as many as half of them haven't been diagnosed. The NHLBI Internet survey of almost 4,200 adults found that 71 percent of respondents said they are aware of COPD, compared with 65 percent in 2008. Awareness was highest among those most at risk, current and former smokers. Awareness was 78 percent among current smokers and 76 percent among former smokers, compared to 69 ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Health Tip: Manage COPD Symptoms

Posted 21 Jul 2011 by Drugs.com

-- Chronic obstructive pulmonary disease (COPD) is an umbrella term for chronic lung diseases that can severely undermine breathing. Examples include chronic bronchitis or emphysema. The National Heart, Lung and Blood Institute offers these suggestions for helping you manage COPD symptoms: Avoid things that are irritating to the lungs, such as cigarette smoke, air pollution, chemical fumes and dust. Work with your doctor for ongoing care and treatment. Continue to take COPD medications exactly as prescribed. Be prepared for a health emergency. Contact your doctor if symptoms worsen. Discuss with your doctor any COPD-related anxiety, depression or stress. Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Arcapta Inhaler Approved for COPD

Posted 5 Jul 2011 by Drugs.com

TUESDAY, July 5 – The Arcapta Neohaler (indacaterol inhalation powder) has been approved by the U.S. Food and Drug Administration for the long-term treatment of chronic obstructive pulmonary disease (COPD). COPD symptoms include airflow obstruction, breathlessness, chronic cough and excessive phlegm, the agency said in a news release. Cigarette smoking is a primary cause of COPD, which includes chronic bronchitis or emphysema. Arcepta, among a class of drugs called beta2-adrenergic agonists, helps relax the lung's airways. It is not intended to treat asthma or the sudden, severe onset of breathing problems associated with COPD, the FDA said. The inhaler was evaluated in a series of clinical studies involving nearly 5,500 people aged 40 and older who had been diagnosed with COPD. Participants all had smoked at least a pack of cigarettes per day for 10 years, and had demonstrated reduced ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Maintenance

No Headway Against COPD, Which Now Affects Women More

Posted 30 Jun 2011 by Drugs.com

WEDNESDAY, June 29 – Between 1998 and 2009 there was no significant decline in cases of the often deadly ailment known as chronic obstructive pulmonary disease (COPD), and the burden of the disease has shifted from men to women, a new report finds. By 2009, 11.8 million Americans aged 18 and over suffered from the progressive respiratory illness – about 1 in every 20 adults, according to the report from the U.S. Centers for Disease Control and Prevention. Just over 6 percent of women now have COPD, the study found, compared to just over 4 percent of men. "COPD is now the third leading cause of death, behind heart disease and cancer," said lead author Dr. Lara J. Akinbami, a medical officer in the Office of Analysis and Epidemiology at the CDC's National Center for Health Statistics. COPD "has replaced stroke, which was the third leading cause of death," she said. "That is mainly ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

For Lung Disorder, Spiriva Beat Serevent in Head-to-Head Trial

Posted 24 Mar 2011 by Drugs.com

WEDNESDAY, March 23 – People with moderate-to-severe chronic obstructive pulmonary disease (COPD) use inhaled long-acting bronchodilators to control symptoms and reduce flare-ups, but which type of drug is best hasn't been clear. Now results have arrived from a new study that pitted two different popular COPD drugs against each other to determine their effectiveness at controlling the disease, which interferes with the flow of air through the lungs and airways. One of the drugs was tiotropium (Spiriva), an anticholinergic, and the other was salmeterol (Serevent), a beta-agonist. The outcome of the trial suggests that Spiriva is more effective at preventing flare-ups, also called exacerbations. "Prevention of exacerbations is a critical treatment goal in the care of COPD patients due to the [illness and death] attributed to exacerbations," said lead study author Dr. Claus Vogelmeier, ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Spiriva, Chronic Obstructive Pulmonary Disease, Maintenance, Serevent Diskus

Increasingly, Other Ailments Prove Fatal for People With COPD

Posted 24 Jan 2011 by Drugs.com

MONDAY, Jan. 24 – People with chronic obstructive pulmonary disease are more likely today than in the past to die from cardiovascular disease or other conditions that are not respiratory ailments, a new Swedish study has found. This suggests that doctors need to be more aware of these risks when treating people with COPD, as the condition is known. In recent years, the average age of COPD patients beginning long-term oxygen therapy has grown in Sweden from 66 to 73 years, Dr. Magnus P. Ekstrom, respiratory medicine physician and researcher at Blekinge Hospital in Karlskrona, Sweden, said in a news release from the American Thoracic Society. The proportion of women starting the therapy also has increased, said Ekstrom, who worked on the study. "We wanted to determine if these changes had resulted in a shift in the causes of death for COPD patients with long-term oxygen therapy," he said ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

IV Steroids May Be Overkill in COPD Patients

Posted 15 Jun 2010 by Drugs.com

TUESDAY, June 15 – Low-dose steroid pills seem to work as well as high doses of injected steroids for patients hospitalized with severe chronic obstructive pulmonary disease (COPD), researchers report. Yet, some 90 percent of these COPD patients are given the higher doses, which is contrary to current prescribing guidelines, claims the study appearing in the June 16 issue of the Journal of the American Medical Association. "We really think that doctors should be following hospital guidelines and treating patients with oral steroids, at least for those who are able to take oral steroids," said Dr. Richard Mularski, author of an accompanying editorial and a pulmonologist with Kaiser Permanente Center for Health Research. Mularski added that he was surprised that this many patients were receiving IV steroids. Patients in crisis with COPD are routinely treated with corticosteroids, ... Read more

Related support groups: Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease, Maintenance, Chronic Obstructive Pulmonary Disease, Acute

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Obstructive Pulmonary Disease

Related Drug Support Groups

albuterol, Symbicort, Spiriva, Ventolin, Advair Diskus, Combivent, Xopenex, Advair HFA, Daliresp, view more... ProAir HFA, ipratropium, Proventil, Atrovent, salmeterol, Ventolin HFA, tiotropium, formoterol, DuoNeb, Alupent, Maxair, Proventil HFA, Brovana, Maxair Autohaler, Atrovent HFA, Foradil Aerolizer, Serevent Diskus, Perforomist, Combivent Respimat, Tornalate, albuterol/ipratropium, Volmax, levalbuterol, Xopenex HFA, Tudorza Pressair, pirbuterol, Arcapta, Metaprel, Ipratropium Inhalation Aerosol, Ipratropium Inhalation Solution, Xopenex Concentrate, Vospire ER, aclidinium, indacaterol, roflumilast, metaproterenol, Airet, AccuNeb, arformoterol, bitolterol, budesonide/formoterol, fluticasone/salmeterol, Respirol